Review Article

The Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Portal Hypertension: Current Status

Gilles Pomier-Layrargues,1 Louis Bouchard,2 Michel Lafortune,2 Julien Bissonnette,1 Dave Guérette,1 and Pierre Perreault2

1 Liver Unit, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada H2X 3J4
2 Department of Radiology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

Correspondence should be addressed to Gilles Pomier-Layrargues, gilles.pomier.layrargues@umontreal.ca

Received 17 April 2012; Accepted 18 May 2012

Academic Editor: Averell Sherker

Copyright © 2012 Gilles Pomier-Layrargues et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The transjugular intrahepatic portosystemic shunt (TIPS) represents a major advance in the treatment of complications of portal hypertension. Technical improvements and increased experience over the past 24 years led to improved clinical results and a better definition of the indications for TIPS. Randomized clinical trials indicate that the TIPS procedure is not a first-line therapy for variceal bleeding, but can be used when medical treatment fails, both in the acute situation or to prevent variceal rebleeding. The role of TIPS to treat refractory ascites is probably more justified to improve the quality of life rather than to improve survival, except for patients with preserved liver function. It can be helpful for hepatic hydrothorax and can reverse hepatorenal syndrome in selected cases. It is a good treatment for Budd Chiari syndrome uncontrollable by medical treatment. Careful selection of patients is mandatory before TIPS, and clinical followup is essential to detect and treat complications that may result from TIPS stenosis (which can be prevented by using covered stents) and chronic encephalopathy (which may in severe cases justify reduction or occlusion of the shunt). A multidisciplinary approach, including the resources for liver transplantation, is always required to treat these patients.

1. Introduction

Portal hypertension is associated with severe and often life-threatening complications. Increased intrahepatic resistance results in increasing splanchic blood flow and development of venous collaterals, which may bleed, and also causes splenomegaly. A hyperdynamic circulation develops with an increased cardiac output and a decrease in systemic vascular resistance. Pooling of splanchic blood may result in a systemic hypovolemia, which can trigger activation of vasoactive systems, mainly vasoconstrictors. This in turn may lead to sodium retention, ascites, and ultimately hepatorenal syndrome [1]. The correction of severe portal hypertension by portacaval shunt surgery has been used for many years, but the morbidity and mortality were high. Moreover, this technique was contraindicated in the presence of liver failure.

The transjugular intrahepatic portosystemic shunt (TIPS) was used for the first time by Rösch et al. in 1969 [2] in dogs and in a cirrhotic patient by Colapinto in 1982 [3]. This treatment was aimed at nonsurgically decreasing portal hypertension. Originally, a tract was created by balloon dilatation of the parenchyma between the hepatic vein and the portal vein after transjugular portal vein catheterization. Unfortunately, this communication closed within days after the procedure. In 1989, the first case of TIPS created with a metallic stent was published by Rössle et al. [4]. This technical advance allowed good long-term patency of the shunt.

Many papers were published in the following years, which led to technical improvements and definition of the best indications for this promising treatment of complications of portal hypertension [5].

In the present paper, technical aspects of this procedure will be described, and the current indications based on the existing literature will be discussed. Contraindications (absolute and relative) will be reported and the potential
complications following the TIPS procedure as well as their treatment will be mentioned.

2. Technical Aspects

TIPS is a hemodynamic equivalent of a side-to-side small diameter surgical portacaval shunt. The experience gained over the last 20 years allows thorough evaluation of the complications of this technique and of its contraindications and indications [5, 6].

This technique is preferably done under general anesthesia [7] but can be performed with deep sedation (particularly for emergency cases). Antibiotic prophylaxis is given even if the literature has not proven the usefulness of this approach, and coagulation defects are corrected before the procedure. After puncture of the jugular vein (most often the right jugular vein) under echographic guidance, a catheter is introduced into one hepatic vein and wedged in the liver parenchyma. Gentle injection of dye allows the retrograde visualisation of intrahepatic portal vein branches [8] (Figure 1). The intrahepatic portal vein then is entered with a modified Ross needle (Cook Medical, Bloomington, IN, USA). CO₂ can be used in patients with renal function impairment to avoid dye nephrotoxicity. Several TIPS sets are commercially available. A guide wire is advanced into the main portal vein. The tract between the hepatic and the portal vein is dilated with an angioplasty balloon catheter (8–10 mm) (Figure 2) followed by stent placement to maintain the communication between both vessels patent (Figure 3). Various TIPS stents can be used (bare stents and PTFE-covered stents). The portacaval gradient after TIPS must be lower than 12 mmHg (the cut-off level associated with complications of portal hypertension) [1, 9].

This technique is now well standardized in specialized centers. The use of ultrasound or transhepatic portography can help localize the intrahepatic portal vein, particularly when anatomic variants or marked liver distortion is observed particularly in cirrhotic patients [8, 10]. Over the years, PTFE-covered stents have replaced bare stents as they markedly improved the long-term patency of the shunt and also prevent portobiliary fistulae [11–13]. The metallic stent should be placed near the junction between the hepatic vein and the vena cava and no more than 1-2 cm below the bifurcation of right and left portal veins. Moreover, the covered part of the stent should not be inside the portal vein as it can block the retrograde intrahepatic portal flow, which may result in intrahepatic portal vein thrombosis. Provided that these principles are followed, liver transplantation can be performed safely without interference of the stent at the time of portal vein and vena cava clamping [14, 15].

3. Contraindications

Contraindications are summarized in Table 1. As mentioned previously, portal hypertension is associated with a hyperdynamic circulation (increased cardiac output, increased
Table 1: Contraindications for the TIPS procedure.

| Absolute                          | Relative                          |
|-----------------------------------|-----------------------------------|
| (i) Right sided heart failure     | (i) Severe liver failure (Pugh score >12) |
| (ii) Biliary tract obstruction    | (ii) Portal vein thrombosis       |
| (iii) Uncontrolled infection       | (iii) Multiple hepatic cysts      |
| (iv) Pulmonary hypertension       |                                   |
| (v) Chronic recurrent disabling hepatic encephalopathy | |
| (vi) Hepatocellular carcinoma involving hepatic veins | |

splanchnic blood flow and decreased systemic resistances). Hemodynamic changes induced by TIPS are spectacular, with a sudden increase in the cardiac output secondary to diversion of splanchnic blood flow into the systemic circulation [16, 17]. Therefore, any impairment in the right ventricle function before TIPS is a problem, as congestive liver failure may be observed after TIPS-induced increase in cardiac output. An evaluation of cardiac function is required before TIPS. On the other hand, even if the hyperdynamic circulation worsens after the procedure, this phenomenon is often transient [16]. The other contraindications are quite obvious. Pre-TIPS chronic recurrent disabling hepatic encephalopathy (HE) is an absolute contraindication, but the onset of an episode of HE induced by precipitants (such as bleeding, sepsis, electrolyte imbalance) before TIPS does not preclude the use of this procedure. The presence of portal vein cavernoma or portal vein thrombosis is no longer an absolute contraindication and may even become an indication as technical advances allow recanalization of the portal vein in some selected cases [18–21]. A transhepatic or a transplenic approach can be helpful to catheterize the main portal vein and facilitates the TIPS procedure.

Many prognostic studies have been published for the prediction of short-term survival after TIPS [22–24]. It is now well recognized that a Pugh score higher than 12 most often represents a contraindication as multiorgan failure occurs in a vast majority of these cases after TIPS [6]. The Meld score has been initially validated as the best predictor of the 3 months survival rate [25–27]. However, TIPS may be performed as a temporary hemostatic measure in a patient already placed on the waiting list for liver transplant.

4. Complications

They are summarized in Tables 2 and 3. Comparison of complication frequency is difficult to evaluate in the literature due to the patient characteristics, the expertise of the center and the study period [28, 29].

4.1. Acute Complications. Acute complications might occur during TIPS placement or within hours or days after the procedure and include neck hematoma, arrhythmia, stent displacement, hemolysis, bilhemia, and shunt thrombosis.

Table 2: Acute complications after TIPS placement.

| Minor or moderate |
|-------------------|
| (i) Neck hematoma |
| (ii) Arrhythmia   |
| (iii) Stent displacement |
| (iv) Hemolysis    |
| (v) Bilhemia      |
| (vi) Hepatic vein obstruction |
| (vii) Shunt thrombosis |
| life threatening  |
| (i) Hemoperitoneum |
| (ii) Hemobilia    |
| (iii) Liver ischemia |
| (iv) Cardiac failure |
| (v) Sepsis        |

Neck hematoma can be prevented by haematological preparation and ultrasound-guided puncture of the jugular vein. Arrhythmia may occur but is self-limited when the distal tip of the guide wire is removed from the right atrium. Bilhemia results from a fistula between a biliary radicle and the portal vein. It must be suspected when a sudden rise of direct bilirubin occurs without any symptoms. It can be proven by shuntography or ERCP and treated by a covered stent across the fistula [30, 31]. Hemolysis is transient and is related to the fragmentation of red blood cells in the metallic stent before endothelialization [32, 33]. The obstruction of a small hepatic vein by a PTFE-covered stent may induce a "segmental" Budd Chiari syndrome with a transient increase in serum bilirubin and transaminases. This phenomenon is self-limited in a majority of the cases [34, 35]. Acute shunt thrombosis (less than 5%) is rare and it is usually due to a portobiliary fistula or in some cases to stent malfunction [36, 37]. The usefulness of phenprocoumon to prevent stent thrombosis is not well established [38]. The shunt can be recanalized but at the same time the fistula must be closed with a covered stent.

Life-threatening complications are very rare (less than 1%) and include hemoperitoneum, hemobilia, liver ischemia, cardiac failure, and sepsis [28]. Hemoperitoneum is most often related to a puncture of the liver capsule; it is usually self-limited. A dissection of the portal vein in its extrahepatic part is life threatening and can be treated with a covered stent. Hemobilia results from a procedure-related fistula between a hepatic artery and the biliary tract. It is treated by embolization. Liver ischemia may follow
Table 4: Risk factors for post-TIPS encephalopathy.

| Parameter          |
|--------------------|
| Age                |
| Gender             |
| Etiology           |
| HE before TIPS     |
| Child-Pugh score   |
| Port hepatogenic gradient |
| Shunt diameter    |
| Creatinine        |
| Indication        |

an accidental catheterization of an intrahepatic artery followed by its thrombosis [39, 40]. Cardiac failure is due to a rapid increase in cardiac output; it may be severe and diuretics can be tried but, in life threatening cases, the obstruction of the shunt may be needed. Finally, sepsis is a potential complication, but antibioprophylaxis can prevent it in a vast majority of cases.

4.2. Chronic Complications. Chronic complications are more frequent and their management may be difficult. Congestive heart failure is related to a high cardiac output following TIPS. Clinically the patients develop sodium retention and right sided heart failure; in severe cases, treatment with diuretics and vasodilators does not work and obstruction of the shunt may be necessary. Portal vein thrombosis is very rare. It occurs more often when the shunt is not correctly placed inside the portal or the hepatic vein, thus obstructing the shunt flow [8]. It may be observed in patients with a hypercoagulable state and in this situation life-long anticoagulation is needed. As observed after surgical portacaval shunt, progressive liver failure may follow TIPS implantation. The first sign is a progressive increase in the serum bilirubin, which is then followed by a rise in INR, onset of encephalopathy, and death due to multiorgan failure within weeks after TIPS. Even if poor pre-TIPS liver function is a risk factor, some patients with a good hepatic reserve may also develop this serious complication after TIPS. Liver transplantation is the only option in this situation.

TIPS is a portacaval shunt; therefore, not surprisingly post-TIPS HE remains a problem. HE episodes are observed in 30–40% of cirrhotic patients, and as opposed to that observed in patients without TIPS, no precipitant can be identified in a majority of cases.

Chronic recurrent disabling HE can occur in 5–10% and may lead to a complete loss of the patient’s autonomy. Several pre-TIPS parameters have been tested to predict post-TIPS hepatic encephalopathy (Table 4). Age, pre-TIPS encephalopathy, and the Pugh score are probably the most useful predictors [41–49]. Prophylaxis with lactulose is not useful [50]. The medical management is difficult and in many cases the only option is to reduce the diameter of the stent or preferably to occlude it [51]. HE clears quickly after the obstruction, but portal hypertension recurs with its associated potential complications (ascites and variceal bleeding). Embolization of varices before TIPS occlusion might be useful measure to prevent variceal rebleeding.

The function of the TIPS is usually evaluated using Doppler ultrasonography. The direction of intrahepatic portal flow, the flow volume in the stent, and the presence of increased velocity in the stent are useful criteria to detect shunt dysfunction and to decide if a shunt revision is needed with an angio graphic intervention [52, 53]. However, the sensitivity and specificity of this modality are only 80–85%. Shunt dysfunction results from an intimal hyperplasia in the stent [54] and is more frequent in the hepatic vein part of the shunt (Figure 4). This phenomenon was observed at 1 year in nearly 80% of cases treated with bare stents and could not be prevented with acetyl salicylic acid [55] or trapidil + ticlopidine [56]. When PTFE-coated stents are used the one-year rate of shunt stenosis is only 10–15% [12] (Figure 3). Treatment includes dilatation of the stenoses and/or implantation of a new covered stent in this area. TIPS involves a foreign material chronically implanted in the liver, and cirrhotic patients are often immunocompromised and therefore susceptible to infection. But, surprisingly, the infection of the stent (the so-called TIPSitis) is exceptional [5]. Diagnostic criteria include repeated episodes of septicaemia without any other detectable source of infection. It is best treated with long-term antibiotherapy [57, 58].

5. Indications

TIPS has been used to treat many complications related to portal hypertension. The relative efficacy of TIPS has been tested with randomized controlled trials, (refractory ascites, variceal bleeding), whereas other indications have been evaluated in uncontrolled case series.

5.1. Gastrointestinal Bleeding

5.1.1. Oesophageal Variceal Bleeding

Primary Prophylaxis. Bleeding from oesophageal varices is a common and severe complication of portal hypertension.

Figure 4: Portography in patient treated one year ago with a TIPS made of a combination of one PTFE-covered stent and one bare stent. Pseudointimal hyperplasia developed only on the bare part of the TIPS (arrows) and induced TIPS dysfunction.
Table 5: Comparison of TIPS and endoscopic and/or pharmacological therapy in the prevention of oesophageal variceal rebleeding (from Zheng et al. [59]).

| Treatment                              | Number of patients | Rebleeding rate n (%) | Encephalopathy n (%) | Mortality n (%) |
|----------------------------------------|--------------------|-----------------------|----------------------|-----------------|
| TIPS                                   | 440                | 86 (19)               | 148 (33)             | 111 (26)        |
| Sclerotherapy/pharmacological therapy  | 443                | 194 (44)              | 86 (19)              | 98 (22)         |

Prevention of the initial bleeding can be achieved in a number of cases by endoscopic variceal ligation or \( \beta \)-blocker treatment. However, TIPS has never been tested in this situation as previous experience with surgical portacaval shunts has clearly demonstrated that this approach is associated with higher morbidity and mortality rates [60].

5.1.2. Acute Bleeding Episode. When an initial bleeding occurs, it is usually controlled with less invasive endoscopic treatment and/or pharmacological therapy. In rare cases bleeding remains uncontrollable, and TIPS has been used as a rescue treatment with good results for bleeding control. However, prognosis relies on the general condition of the patient, the value of the liver function reserve, and the associated comorbidities [61–64]. However, a recent randomized controlled trial evaluated the use of emergent TIPS as compared to standard medical therapy in patients with severe portal hypertension and a Pugh score of 7 to 13 [65]. Treatment failure was more frequent in the medical group (50% versus 12%) and the survival rate was better in the TIPS group (11 versus 38%). This approach could justify the use of TIPS early after bleeding episodes in patients with moderate or severe liver failure and severe portal hypertension. These promising results are in line with that observed in a case series of cirrhotic patients Child A or B who underwent emergency portacaval shunt surgery [66] but should be confirmed by other controlled trials.

5.1.3. Secondary Prophylaxis. Bleeding tends to recur frequently after a first episode. \( \beta \)-blockers and variceal band ligation have both been demonstrated to lower the incidence of rebleeding [1]. TIPS has been tested against these two modalities in several prospective controlled trials [67–78]. Meta-analyses have demonstrated that TIPS was more efficient in preventing rebleeding but it was more frequently followed by episodes of encephalopathy, and survival was not different between groups [59, 79, 80] (Table 5). TIPS has also been compared with surgical shunts or oesophageal transaction [81–83], but results are difficult to interpret because all the patients were good operative risks, and the studies were performed before the introduction of PTFE-coated stents. Therefore, TIPS is not recommended as a first-line therapy for secondary prophylaxis of variceal bleeding.

5.1.4. Gastric Variceal Bleeding. Bleeding from gastric varices is often severe and difficult to control, particularly when fundal varices are involved. The first-line treatment is endoscopic sclerotherapy with cyanoacrylate [84]. TIPS has been used in a number of uncontrolled trials in patients in whom endoscopic therapy failed [85, 86]. A recent controlled trial has shown that TIPS is more efficient than cyanoacrylate in prevention of rebleeding (secondary prophylaxis) from large gastric varices [87]. This interesting finding must be confirmed by other groups and after a long-term followup. It should be mentioned that due to the large size of fundal varices, the risk of rupture is still present even at a low portacaval gradient (<12 mmHg) after TIPS [88, 89]. This is probably best explained by the relationship between the variceal tension (and therefore the risk of rupture) and the variceal size. For this reason, it is now recommended to embolize gastric varices at the time of TIPS placement [90] (Figures 5 and 6).

5.1.5. Ectopic Varices. Varices may develop anywhere along the digestive tract in patients with portal hypertension (duodenum, jejunum, colon, rectum, stomies) and may bleed. Local treatments are either impossible or associated with a high rate of rebleeding. The best approach is the TIPS procedure, which can be combined with embolization of the varices [91, 92] (Figure 7).

5.1.6. Portal Hypertensive Gastropathy. These gastric lesions rarely induce problematic bleeding. Anecdotal case reports suggest that TIPS may control bleeding in these patients [93].

5.1.7. Gastric Antral Vascular Ectasia (GAVE). Chronic bleeding from GAVE may be difficult to manage. However, TIPS does not help to control haemorrhage, probably because these vascular lesions are related to liver disease and not to portal hypertension [93–95].
5.2. Ascites. Ascites is a frequent complication of portal hypertension. It may become resistant to medical treatment in nearly 5–10% of cases [97], and the TIPS procedure has been evaluated for this situation in case series [98–100] and several prospective randomized controlled trials [101–106]. TIPS-induced decrease in portal pressure leads to a good control of ascites in a majority of cases and more often than repeated large volume paracentesis. However, hepatic encephalopathy is observed more frequently, and survival is not improved in a majority of trials [96, 107, 108] (Table 6). However, a recent meta-analysis showed different results after analysing individual data [109]. Moreover, a recent study demonstrated that survival was better in the TIPS group as compared to the paracentesis group; it should be mentioned that in this study, the patients had good liver and renal function [103]. Therefore, this issue is still controversial. There is no clinical controlled trial on the long-term efficacy of PTFE-covered stents in the treatment of refractory ascites. It is now agreed that TIPS may be offered to cirrhotic patients with moderately impaired liver function, without organic kidney disease and preferably in younger patients (less than 65 years) [1]. Liver transplantation should be considered as a backup in case of TIPS failure [110]. The quality of life must be also be considered in the decision making process [111] if transplantation is not an option.

5.3. Pleural Effusion. This is an equivalent of ascites, but the tolerance is poor as only a limited amount of fluid in the pleural may induce disabling dyspnea. Repeated pleural drainage is often associated with infection of the fluid. TIPS is a good option, but the risks of severe hepatic encephalopathy and/or liver failure following TIPS are similar to that observed in ascitic patients [112–114].

5.4. Hepatorenal Syndrome. The chronic form of functional renal failure associated with ascites (hepatorenal syndrome type 2) is usually reversible after TIPS; by contrast, hepatorenal syndrome type 1 which is progressive, more severe, and associated with progressive liver failure usually responds less well as TIPS may aggravate the liver insufficiency [115–117]. It has no role in these patients except for highly selected cases as a bridge to liver transplantation.

5.5. Budd Chiari Syndrome. The management of this syndrome includes diuretic therapy and chronic anticoagulation therapy. In refractory cases, surgical side-to-side portacaval shunt has been used in the past but is no longer used due to the operative risks and the conflicting results [118]. TIPS, which is a nonsurgical equivalent, has been widely tested and demonstrated promising results (control of ascites, reversal of liver failure) in large series [119, 120]; however, the technique of TIPS placement is difficult given the absence of hepatic veins and the caudate lobe hypertrophy (Figures 8, 9 and 10). These patients must be anticoagulated life long. There is no controlled trial comparing TIPS with liver transplantation, but the good results observed after TIPS justify its use first, transplantation being considered in TIPS failure.

5.6. Veno-Occlusive Disease. Several case reports have evaluated the TIPS procedure in the treatment of veno-occlusive disease with some good results [121, 122].

---

Table 6: Comparison of TIPS and large volume paracentesis in the treatment of refractory ascites (from D’Amico et al. [96]).

| Treatment     | Number of patients | Recurrence of ascites n (%) | Encephalopathy n (%) | Mortality n (%) |
|---------------|--------------------|-----------------------------|----------------------|-----------------|
| TIPS          | 149                | 66 (44%)                    | 72 (48%)             | 69 (46%)        |
| Paracentesis  | 156                | 135 (87%)                   | 51 (33%)             | 82 (54%)        |
5.7. Miscellaneous Indications

5.7.1. Preoperative TIPS. It has been suggested that relief of portal hypertension before abdominal surgery in cirrhotic patients could decrease the perioperative bleeding and postoperative complications, such as, ascitic leak [123]. However, TIPS-associated complications are not infrequent [124]; the best candidates for preoperative TIPS are cirrhotic patients with well-preserved or moderately impaired liver function (Pugh class A or B) and a significant amount of venous collaterals in the operative area. It should also be mentioned that preoperative TIPS would prevent the formation of stomal varices after surgery, which often induce recurrent bleeding (Figure 7).

5.7.2. Hepatopulmonary Syndrome. A recent review reports 6 cases of hepatopulmonary syndrome with an improvement in oxygenation after TIPS placement in 5 patients [125–127]. The rationale of this approach is difficult to understand as worsening of vasodilatation usually follows the TIPS procedure, which could aggravate hypoxemia. Therefore, the mechanism of action is unknown.

6. The TIPS Unit

Experience with this procedure over last 20 years clearly demonstrates the need for a multidisciplinary approach. First of all, the indications for TIPS should be discussed rigorously according to a risk benefit approach; preoperative evaluation should include not only the liver function parameters, the cardiac function, but also the assessment of the comorbidities and the evaluation of the risks of post-TIPS chronic encephalopathy. The benefits of TIPS implantation must be weighed against that of liver transplantation. Therefore, hepatologists (or gastroenterologists), cardiologists, interventional radiologists, intensive care specialists, and transplant surgeons play a role in the decision making process. Primary patency higher than 90% after the TIPS placement is a prerequisite in such a TIPS unit. Followup is also crucial as post-TIPS complications may occur and must be treated. Ideally, these patients must be followed regularly in a specialized TIPS clinic, and the surveillance of the TIPS function as well as screening for hepatocarcinoma is mandatory. The collaboration of a highly trained nurse is essential.

7. Conclusions

The TIPS procedure is now a well-established treatment of complications of portal hypertension. Technical advances and well-designed clinical studies provide a scientific basis to define the best indications. Cost effectiveness analysis must be done in the future taking into account recent developments (technical improvements, better selection of patients, and better management after TIPS). However,
severe complications still exist and have to be addressed as stated in a recent editorial [128].

Acknowledgments

The authors wish to thank Mr. Jacques Bernard for technical assistance, Mrs. Manon Bourcier for editing the paper, and Mrs. Annette Hollmann for reviewing the English of this paper.

References

[1] A. J. Sanyal, J. Bosch, A. Blei, and V. Arroyo, “Portal hypertension and its complications,” Gastroenterology, vol. 134, no. 6, pp. 1715–1728, 2008.
[2] J. Rösch, W. N. Hanane, and H. Snow, “Transjugular portal venography and radiologic portacaval shunt: an experimental study,” Radiology, vol. 92, no. 5, pp. 1112–1114, 1969.
[3] R. F. Colapinto, R. D. Stronell, S. J. Birch et al., “Creation of an intrahepatic portosystemic shunt with a Gruntzig balloon catheter,” Canadian Medical Association Journal, vol. 126, no. 3, pp. 267–268, 1982.
[4] M. Rössle, G. M. Richter, G. Noldge, J. C. Palmaz, W. Wenz, and W. Gerok, “New non-operative treatment for variceal haemorrhage,” The Lancet, vol. 2, no. 8655, p. 153, 1989.
[5] T. D. Boyer and Z. J. Haskal, “The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009,” Hepatology, vol. 51, no. 1, pp. 1–16, 2010.
[6] Z. Hassoun and G. Pomier-Layrargues, “The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 1, pp. 1–4, 2004.
[7] A. Degasperi, A. Corti, R. Corso et al., “Transjugular intrahepatic portosystemic shunt (TIPS): the anesthesiological point of view after 150 procedures managed under total intravenous anesthesia,” Journal of Clinical Monitoring and Computing, vol. 23, no. 6, pp. 341–346, 2009.
[8] M. Easa and T. Clark, “Transjugular intrahepatic portosystemic shunt: state of the art,” Seminars in Roentgenology, vol. 46, no. 2, pp. 125–132, 2011.
[9] M. Casado, J. Bosch, J. C. Garcia-Pagan et al., “Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings,” Gastroenterology, vol. 114, no. 6, pp. 1296–1303, 1998.
[10] T. Scanlon and R. K. Ryu, “Portal vein imaging and access for transjugular intrahepatic portosystemic shunts,” Techniques in Vascular and Interventional Radiology, vol. 11, no. 4, pp. 217–224, 2008.
[11] B. Angermayr, M. Cejna, F. Koenig et al., “Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents,” Hepatology, vol. 38, no. 4, pp. 1043–1050, 2003.
[12] C. Bureau, J. C. G. Pagan, G. P. Layrargues et al., “Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study,” Liver International, vol. 27, no. 6, pp. 742–747, 2007.
[13] M. Cejna, M. Peck-Radosavljevic, S. A. Thurnher, K. Hittmair, M. Schoder, and J. Lammer, “Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesi,” Radiology, vol. 221, no. 2, pp. 437–446, 2001.
[14] G. P. Guerrini, M. Pleuguezuelo, S. Maimone et al., “Impact of tips preliver transplantation for the outcome posttransplantation,” American Journal of Transplantation, vol. 9, no. 1, pp. 192–200, 2009.
[15] D. Tripathi, G. Theraponos, D. N. Redhead, K. K. Madhavan, and P. C. Hayes, “Transjugular intrahepatic portosystemic stent-shunt and its effects on orthotopic liver transplantation,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 8, pp. 827–832, 2002.
[16] L. A. Colombato, L. Spahr, J. P. Martinet et al., “Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients,” Gut, vol. 39, no. 4, pp. 600–604, 1996.
[17] M. Merli, V. Valeriano, S. Funaro et al., “Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (tips),” American Journal of Gastroenterology, vol. 97, no. 1, pp. 142–148, 2002.
[18] F. Fanelli, S. Angeloni, F. M. Salvatori et al., “Transjugular intrahepatic portosystemic shunt with expanded-polytetrafluoroethylene-covered stents in non-cirrhotic patients with portal cavernoma,” Digestive and Liver Disease, vol. 43, no. 1, pp. 78–84, 2011.
[19] G. Han, X. Qi, C. He et al., “Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis,” Journal of Hepatology, vol. 54, no. 1, pp. 78–88, 2011.
[20] M. Senzolo, P. Burra, D. Patch, and A. K. Burroughs, “Tips for portal vein thrombosis (pvt) in cirrhosis: not only unblocking a pipe,” Journal of Hepatology, vol. 55, no. 4, pp. 945–946, 2011.
[21] A. Wils, E. Van Der Linden, B. Van Hoek, and P. M. T. Pattynama, “Transjugular intrahepatic portosystemic shunt in patients with chronic portal vein occlusion and cavernous transformation,” Journal of Clinical Gastroenterology, vol. 43, no. 10, pp. 982–984, 2009.
[22] N. Chalasani, W. S. Clark, L. G. Martin et al., “Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting,” Gastroenterology, vol. 118, no. 1, pp. 138–144, 2000.
[23] D. Patch, V. Nikolopoulou, A. McCormick et al., “Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding,” Journal of Hepatology, vol. 28, no. 3, pp. 454–460, 1998.
[24] S. S. Rouillard, N. M. Bass, J. P. Roberts et al., “Severe hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts: natural history and predictors of outcome,” Annals of Internal Medicine, vol. 128, no. 5, pp. 374–377, 1998.
[25] M. Malinchoc, P. S. Kamath, F. D. Gordon, C. J. Peine, J. Rank, and P. C. Ter Borg, “A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts,” Hepatology, vol. 31, no. 4, pp. 864–871, 2000.
[26] F. Salerno, M. Merli, M. Cazzaniga et al., “MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt,” Journal of Hepatology, vol. 56, no. 4, pp. 494–500, 2002.
[27] M. Schepeke, F. Roth, R. Fimmers et al., “Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic extrahepatic portosystemic shunting,” Canadian Medical Association Journal, vol. 118, no. 1, pp. 138–144, 2000.
portosystemic shunting,” *American Journal of Gastroenterology*, vol. 98, no. 5, pp. 1167–1174, 2003.

[28] R. C. Gaba, V. L. Khiatan, M. G. Knuttinen et al., “Comprehensive review of TIPS technical complications and how to avoid them,” *American Journal of Roentgenology*, vol. 196, no. 3, pp. 673–685, 2011.

[29] A. M. Freedman, A. J. Sanayal, J. Tisnado et al., “Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review,” *Radiographics*, vol. 13, no. 6, pp. 1185–1210, 1993.

[30] S. Mallery, M. L. Freeman, C. J. Peine, R. P. Miller, and W. R. Stanchfield, “Biliary-shunt fistula following transjugular intrahepatic portosystemic shunt placement,” *Gastroenterology*, vol. 111, no. 5, pp. 1535–1537, 1996.

[31] L. Spahr, A. Sahai, R. Lahaie et al., “Transient healing of TIPS-induced biliovenous fistula by PTFE-covered stent graft,” *Digestive Diseases and Sciences*, vol. 41, no. 11, pp. 2229–2232, 1996.

[32] H. O. Conn, “Hemolysis after transjugular intrahepatic portosystemic shunting: the naked stent syndrome,” *Hepatology*, vol. 23, no. 1, pp. 177–181, 1996.

[33] A. J. Sanayal, A. M. Freedman, P. P. Purdum, M. L. Shiffman, and V. A. Luketic, “The hematologic consequences of transjugular intrahepatic portosystemic shunts,” *Hepatology*, vol. 23, no. 1, pp. 32–39, 1996.

[34] C. Bureau, P. Otal, V. Chabbert, J. M. Péron, H. Rousseau, and J. P. Vinel, “Segmental liver ischemia after TIPS procedure using a new PTFE-covered stent,” *Hepatology*, vol. 36, no. 6, p. 1554, 2002.

[35] S. Ditisheim, M. P. Sylvestre, L. Bouchard et al., “Transient segmental hepatic ischemia following PTFE-coated TIPS stent implantation does not influence the clinical outcome in cirrhotic patients,” *Gastroenterology*, vol. 142, no. 5, Supplement, p. S946, 2012.

[36] R. Jalan, D. J. Harrison, D. N. Redhead, and P. C. Hayes, “Transjugular intrahepatic portosystemic stent-shunt (TIFSS) occlusion and the role of biliary venous fistulae,” *Journal of Gastroenterology*, vol. 24, no. 2, pp. 169–176, 1996.

[37] R. R. Saxon, J. Mendel-Hartvig, C. L. Corless et al., “Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine,” *Journal of Vascular and Interventional Radiology*, vol. 7, no. 4, pp. 487–497, 1996.

[38] P. Sauer, L. Theilmann, S. Herrmann et al., “Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial,” *Hepatology*, vol. 24, no. 6, pp. 1433–1436, 1996.

[39] Z. J. Haskal, M. J. Pentecost, and R. A. Rubin, “Hepatic arterial injury after transjugular intrahepatic portosystemic shunt placement: report of two cases,” *Radiology*, vol. 188, no. 1, pp. 85–88, 1993.

[40] P. M. T. Pattynama, B. van Hoek, and L. J. S. Kool, “Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion,” *CardioVascular and Interventional Radiology*, vol. 18, no. 3, pp. 192–195, 1995.

[41] M. Bai, X. Qi, Z. Yang et al., “Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review,” *Journal of Gastroenterology and Hepatology*, vol. 26, no. 6, pp. 943–951, 2011.

[42] M. Guevara, M. E. Baccaro, J. Rios et al., “Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration,” *Liver International*, vol. 30, no. 8, pp. 1137–1142, 2010.

[43] Z. Hassoun, M. Deschenes, M. Lafontaine et al., “Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy,” *American Journal of Gastroenterology*, vol. 96, no. 4, pp. 1205–1209, 2001.

[44] R. Jalan, R. A. Elton, D. N. Redhead, N. D. C. Finlayson, and P. C. Hayes, “Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage,” *Journal of Hepatology*, vol. 23, no. 2, pp. 123–128, 1995.

[45] W. Nolte, J. Wiltfang, C. Schindler et al., “Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations,” *Hepatology*, vol. 28, no. 5, pp. 1215–1225, 1998.

[46] O. Riggio, S. Angeloni, F. M. Salvatori et al., “Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts,” *American Journal of Gastroenterology*, vol. 103, no. 11, pp. 2738–2746, 2008.

[47] O. Riggio, L. Ridola, S. Angeloni et al., “Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial,” *Journal of Hepatology*, vol. 53, no. 2, pp. 267–272, 2010.

[48] A. J. Sanayal, A. M. Freedman, M. L. Shiffman, P. P. Purdum, V. A. Luketic, and A. K. Cheatham, “Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study,” *Hepatology*, vol. 20, no. 11, pp. 46–55, 1994.

[49] S. Masson, H. A. Mardini, J. D. Rose, and C. O. Record, “Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience,” *Journal of the Association of Physicians*, vol. 101, no. 6, pp. 493–501, 2008.

[50] O. Riggio, A. Masini, C. Efrati et al., “Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study,” *Journal of Hepatology*, vol. 42, no. 5, pp. 674–679, 2005.

[51] R. K. Kerlan Jr., J. M. LaBerge, E. L. Baker et al., “Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts,” *Journal of Vascular and Interventional Radiology*, vol. 6, no. 6, pp. 917–921, 1995.

[52] M. Lafontaine, J. P. Martinet, A. Denys et al., “Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/manometric correlative study,” *American Journal of Roentgenology*, vol. 164, no. 4, pp. 997–1002, 1995.

[53] J. Žižka, P. Eliáš, A. Krajina et al., “Value of Doppler sonography in revealing transjugular intrahepatic portosystemic shunt malfunction: a 5-year experience in 216 patients,” *American Journal of Roentgenology*, vol. 175, no. 1, pp. 141–148, 2000.

[54] H. Ducoin, J. El-Khoury, H. Rousseau et al., “Histopathologic analysis of transjugular intrahepatic portosystemic shunts,” *Hepatology*, vol. 25, no. 5, pp. 1064–1069, 1997.
[82] W. S. Helton, R. Maves, K. Wicks, and K. Johansen, “Transjugular intrahepatic portosystemic shunt vs surgical shunt in good-risk cirrhotic patients: a case-control comparison,” Archives of Surgery, vol. 136, no. 1, pp. 17–20, 2001.

[83] J. M. Henderson, T. D. Boyer, M. H. Kutner et al., “Distal splenorenal shunt versus transjugular intrahepatic portal systemic shunt for variceal bleeding: a randomized trial,” Gastroenterology, vol. 130, no. 6, pp. 1643–1651, 2006.

[84] S. Imani, K. Kowdley, and R. Kozarek, “Gastric varices: an updated review of management,” Journal of Clinical Gastroenterology, vol. 45, no. 2, pp. 133–148, 2011.

[85] K. Barange, J. M. Péron, K. Imani et al., “Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices,” Hepatology, vol. 30, no. 5, pp. 1139–1143, 1999.

[86] T. N. Chau, D. Patch, Y. W. Chan, A. Nagral, R. Dick, and A. K. Burroughs, “Salvage transjugular intrahepatic portosystemic shunts; gastric fundal compared with esophageal variceal bleeding,” Gastroenterology, vol. 114, no. 5, pp. 981–987, 1998.

[87] G. H. Lo, H. L. Liang, W. C. Chen et al., “A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding,” Endoscopy, vol. 39, no. 8, pp. 679–685, 2007.

[88] L. Spahr, M. P. Dufresne, B. T. Bui et al., “Efficacy of TIPS in the prevention of rebleeding from esophageal and fundal varices: a comparative study,” Hepatology, vol. 22, no. 4, Abstract A296, 1995.

[89] D. Tripathi, G. Therapondos, E. Jackson, D. N. Redhead, and P. C. Hayes, “The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations,” Gut, vol. 51, no. 2, pp. 270–274, 2002.

[90] I. K. Tesdal, T. Filser, C. Weiss, E. Holm, C. Duerer, and W. Jaschke, “Transjugular intrahepatic portosystemic shunts: adjunctive embolotherapy of gastroesophageal collateral vessels in the prevention of variceal rebleeding,” Radiology, vol. 236, no. 1, pp. 360–367, 2005.

[91] M. Vangi, D. Patch, N. Terreni et al., “Bleeding ectopic varices—treatment with transjugular intrahepatic portosystemic shunt (TIPSS) and embolisation,” Journal of Hepatology, vol. 41, no. 4, pp. 560–566, 2004.

[92] V. Vidal, L. Joly, P. Perreault, L. Bouchard, M. Lafortune, and G. Pomier-Layrargues, “Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients,” Cardiovascular and Interventional Radiology, vol. 29, no. 2, pp. 216–219, 2006.

[93] P. S. Kamath, M. Lacerda, D. A. Ahlquist, M. A. McKusick, J. C. Andrews, and D. A. Nagorney, “Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis,” Gastroenterology, vol. 118, no. 5, pp. 905–911, 2000.

[94] L. Spahr, J. P. Villeneuve, M. P. Dufresne et al., “Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension,” Gut, vol. 44, no. 5, pp. 739–742, 1999.

[95] C. Vincent, G. Pomier-Layrargues, M. Dagenais et al., “Care of gastric antral vascular ectasia by liver transplantation despite persistent portal hypertension: a clue for pathogenesis,” Liver Transplantation, vol. 8, no. 8, pp. 717–720, 2002.

[96] G. D’Amico, A. Luca, A. Morabito, R. Miraglia, and M. D’Amico, “Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis,” Gastroenterology, vol. 129, no. 4, pp. 1282–1293, 2005.

[97] V. Arroyo, P. Gimés, A. L. Gerbes et al., “Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis,” Hepatology, vol. 23, no. 1, pp. 164–176, 1996.

[98] M. Deschênes, M. P. Dufresne, B. Bui et al., “Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites,” American Journal of Gastroenterology, vol. 94, no. 5, pp. 1361–1365, 1999.

[99] J. P. Martinet, D. Fenyes, L. Legault et al., “Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution,” Digestive Diseases and Sciences, vol. 42, no. 1, pp. 161–166, 1997.

[100] U. Thalheimer, G. Leandro, D. N. Samonakis et al., “TIPS for refractory ascites: a single-centre experience,” Journal of Gastroenterology, vol. 44, no. 10, pp. 1089–1095, 2009.

[101] P. Gines, J. Uriz, B. Calahorra et al., “Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis,” Gastroenterology, vol. 123, no. 6, pp. 1839–1847, 2002.

[102] D. Lebrec, N. Giuly, A. Hadenouge et al., “Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial,” Journal of Hepatology, vol. 25, no. 2, pp. 135–144, 1996.

[103] Y. Narahara, H. Kanazawa, T. Fukuda et al., “Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial,” Journal of Gastroenterology, vol. 46, no. 1, pp. 78–85, 2011.

[104] M. Rössle, A. Ochs, V. Gülberg et al., “A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites,” New England Journal of Medicine, vol. 342, no. 23, pp. 1701–1707, 2000.

[105] F. Salerno, M. Merli, O. Riggio et al., “Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites,” Hepatology, vol. 40, no. 3, pp. 629–635, 2004.

[106] A. J. Sanyal, C. Genninger, K. R. Reddy et al., “The North American study for the treatment of refractory ascites,” Gastroenterology, vol. 124, no. 3, pp. 634–641, 2003.

[107] A. Albillos, R. Bañares, M. González, M. V. Catalina, and L. M. Molinero, “A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites,” Journal of Hepatology, vol. 43, no. 6, pp. 990–996, 2005.

[108] P. Deltenre, P. Mathurin, S. Dharancy et al., “Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis,” Liver International, vol. 25, no. 2, pp. 349–356, 2005.

[109] F. Salerno, C. Cammà, M. Enea, M. Rössle, and F. Wong, “Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data,” Gastroenterology, vol. 133, no. 3, pp. 825–834, 2007.

[110] P. Gines, P. Angeli, K. Lenz et al., “EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis,” Journal of Hepatology, vol. 53, no. 3, pp. 397–417, 2010.

[111] M. S. Campbell, C. M. Brensinger, A. J. Sanyal et al., “Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy,” Hepatology, vol. 42, no. 3, pp. 635–640, 2005.

[112] R. Dhanasekaran, J. K. West, P. C. Gonzales et al., “Transjugular intrahepatic portosystemic shunt for symptomatic
refractory hepatic hydrothorax in patients with cirrhosis,” *American Journal of Gastroenterology*, vol. 105, no. 3, pp. 635–641, 2010.

[113] V. Siegerstetter, P. Deibert, A. Ochs, M. Olschewski, H. E. Blum, and M. Rössle, “Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients,” *European Journal of Gastroenterology and Hepatology*, vol. 13, no. 5, pp. 529–534, 2001.

[114] F. D. Gordon, H. T. Anastopoulos, W. Crenshaw et al., “The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt,” *Hepatology*, vol. 25, no. 6, pp. 1366–1369, 1997.

[115] K. A. Brensing, J. Textor, J. Perz et al., “Long term outcome after transjugular intrahepatic portosystemic stent—shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study,” *Gut*, vol. 47, no. 2, pp. 288–295, 2000.

[116] M. Guevara, P. Ginès, J. C. Bandi et al., “Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems,” *Hepatology*, vol. 28, no. 2, pp. 416–422, 1998.

[117] L. Spahr, D. Fenyves, V. V. N’Guyen et al., “Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt,” *American Journal of Gastroenterology*, vol. 90, no. 7, pp. 1169–1171, 1995.

[118] T. Orug, Z. F.Soonawalla, K. Tekin, S. P. Olliff, J. A. C. Buckels, and A. D. Mayer, “Role of surgical portosystemic shunts in the era of interventional radiology and liver transplantation,” *British Journal of Surgery*, vol. 91, no. 6, pp. 769–773, 2004.

[119] J. C. Garcia-Pagán, M. Heydtmann, S. Raffa et al., “TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 Patients,” *Gastroenterology*, vol. 135, no. 3, pp. 808–815, 2008.

[120] A. Perelló, J. C. García-Pagán, R. Gilabert et al., “TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy,” *Hepatology*, vol. 35, no. 1, pp. 132–139, 2002.

[121] M. W. Fried, D. G. Connaghan, S. Sharma et al., “Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation,” *Hepatology*, vol. 24, no. 3, pp. 588–591, 1996.

[122] F. O. Smith, M. S. Johnson, L. R. Scherer et al., “Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease,” *Bone Marrow Transplantation*, vol. 18, no. 3, pp. 643–646, 1996.

[123] D. Azoulay, F. Buabse, I. Damiano et al., “Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension,” *Journal of the American College of Surgeons*, vol. 193, no. 1, pp. 46–51, 2001.

[124] E. Vinet, P. Perreault, L. Bouchard et al., “Transjugular intrahepatic portosystemic shunt before abdominal surgery in cirrhotic patients: a retrospective, comparative study,” *Canadian Journal of Gastroenterology*, vol. 20, no. 6, pp. 401–404, 2006.

[125] H. M. Lasch, M. W. Fried, S. L. Zacks et al., “Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome,” *Liver Transplantation*, vol. 7, no. 2, pp. 147–149, 2001.

[126] A. S. Paramesh, S. Z. Husain, B. Shneider et al., “Improvement of hepatopulmonary syndrome after transjugular intrahepatic portosystemic shunting: case report and review of literature,” *Pediatric Transplantation*, vol. 7, no. 2, pp. 157–162, 2003.

[127] J. L. Riegler, K. A. Lang, S. P. Johnson, and J. H. Westerman, “Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome,” *Gastroenterology*, vol. 109, no. 3, pp. 978–983, 1995.

[128] O. Riggio, L. Ridola, C. Lucidi, and S. Angeloni, “Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertensive: time to update the guidelines?” *Digestive and Liver Disease*, vol. 42, no. 7, pp. 462–467, 2010.